Genzyme re-ups and beefs up business with Hospira for fill/finish ops

Genzyme will have Hospira conduct the final steps of manufacturing for a growing list of drugs under a new supply agreement. Hospira will provide fill/finish services for Cerezyme, Fabrazyme, Thyrogen and Myozyme, as it has been according to a previous agreement, as well as Lumizyme, Thymoglobulin, Campath and products in development. Article

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.